BROVANA® (arformoterol tartrate) Inhalation Solution: Improved lung function within minutes
- BROVANA® (arformoterol tartrate) is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers2
- BROVANA should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition
- BROVANA should not be used with other medications containing long-acting beta2-agonists
*Data from 2 identical 12-week, double-blind, placebo-controlled, randomized, multicenter trials (trials A & B) assessing the efficacy and tolerability of nebulized BROVANA 15 mcg twice daily (n=288) vs placebo (n=293) in patients with COPD.
†Data are pooled from clinical trials A and B at Week 0, Day 1.
‡Data are pooled from clinical trials A and B over 12 weeks.